Evidence map›Paper›PMID 27116033›Full record

ReviewChromosoma2016

Transformation-associated recombination (TAR) cloning for genomics studies and synthetic biology.

Natalay Kouprina, Vladimir Larionov

Abstract readReview
In one paragraph

Review in Chromosoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The design and engineering of synthetic genomes.Nature reviews. Genetics · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cloning and sequencing analysis of wholeFrontiers in microbiology · 2024
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Natalay KouprinaDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, 20892, USA. kouprinn@mail.nih.gov.
Vladimir LarionovDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, 20892, USA.
National Cancer Institute · US

Funding

Study of hereditary prostate cancer and human artificial chromosomesZIABC010413 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LARIONOV, VLADIMIR · 2009 to 2025
$31.5M
Study of hereditary prostate cancer and human artificial chromosomesZ01BC010413 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LARIONOV, VLADIMIR · 2000 to 2008
$2.4M
Intramural NIH HHS Z01 BC010413
6 · The paper itself

Abstract

Transformation-associated recombination (TAR) cloning represents a unique tool for isolation and manipulation of large DNA molecules. The technique exploits a high level of homologous recombination in the yeast Sacharomyces cerevisiae. So far, TAR cloning is the only method available to selectively recover chromosomal segments up to 300 kb in length from complex and simple genomes. In addition, TAR cloning allows the assembly and cloning of entire microbe genomes up to several Mb as well as engineering of large metabolic pathways. In this review, we summarize applications of TAR cloning for functional/structural genomics and synthetic biology.

Indexed as

AllelesChromosomes, Artificial, HumanCloning, MolecularPlasmodium falciparumRecombination, GeneticSaccharomyces cerevisiaeSynthetic BiologyTrypanosoma brucei bruceiHACHuman artificial chromosomeSynthetic biologyTAR cloningTransformation-associated recombination

Identifiers

PMID27116033
PMCPMC5025352
OpenAlexW2343690806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.